EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with type 1 or 2 diabetes. This case in an older adult with longstanding type 1 diabetes shows how EIAS can be managed in an outpatient setting.
Once-weekly insulins offer a way to simplify therapy and reduce the treatment burden for people with type 2 diabetes, and also have potential for individuals with type 1 diabetes.
SGLT2 inhibitors reduce the risk of incident gout and gout flares in patients with type 2 diabetes and offer cardiovascular benefits, compared with sulfonylureas.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with type 1 or 2 diabetes. This case in an older adult with longstanding type 1 diabetes shows how EIAS can be managed in an outpatient setting.
Rapidly progressive insulin-dependent diabetes in the absence of islet autoantibodies developed 2 years after starting treatment with the immune checkpoint inhibitor nivolumab.
HC-HB is a rare movement disorder that can occur in patients with poorly controlled diabetes and hyperglycemia without ketoacidosis. The mainstay of treatment is prompt correction of hyperglycemia.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Diabetes mellitus (DM) and premenstrual syndrome (PMS) are global health challenges. Both disorders are often linked to a range of physical and psychological symptoms that significantly impact the quality of life of many women. Yet, the exact …
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in the USA. Atherosclerotic CVD (ASCVD) is the most common type of CVD and affects approximately 25 million US adults [ 1 , 2 ]. Dyslipidemia and type 2 diabetes …
It is well known that vitamin D has a profound effect on calcium and bone metabolism, but its influence on other organs (extraskeletal effect) has been proposed. Consistently, vitamin D deficiency is associated with an increased incidence of …
Pregnancy complications are diseases occurring during pregnancy that are not directly caused by pregnancy. They include a variety of conditions such as hypertensive disorders of pregnancy (HDP), gestational diabetes mellitus (GDM), and …
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
An independent educational program featuring simulated patient consultations. Make knowledge-based decisions on diagnosis and management of CKD with and without co-morbidities, and learn from experts Kevin Fernando and David Wheeler.
An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
The comorbidity of cardiovascular disease (CVD) in relation to chronic kidney disease (CKD) is alarmingly high [ 1 ], as it currently constitutes the most common cause of death in the patient group [ 2 ]. Hence, the KDIGO guidelines recommend that …
Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are an effective class of drugs for the treatment of type 2 diabetes mellitus (T2D), with well-defined safety and tolerability profiles. Their use is associated with better glycemic control and …
Pneumococcal disease is a leading cause of hospitalization in the elderly and in patients with chronic comorbidities [ 1 ]. Individuals with diabetes (DM) are at increased risk for bacteremic forms of pneumococcal infection with mortality rates as …
Globally, 537 million adults were living with diabetes in 2021, and this figure is expected to increase to 783 million by 2045 [ 1 ]. An estimated 90% of people with diabetes have type 2 diabetes (T2D) [ 2 ].
The use of metformin as a treatment for gestational diabetes is controversial, but it costs less than insulin and is administered orally. This review assesses the available data on metformin’s safety and efficacy for mother and child.
EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with type 1 or 2 diabetes. This case in an older adult with longstanding type 1 diabetes shows how EIAS can be managed in an outpatient setting.
EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with type 1 or 2 diabetes. This case in an older adult with longstanding type 1 diabetes shows how EIAS can be managed in an outpatient setting.
